Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers

Yue SUI1, Jianping CHEN1,2✉

1. School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
2. Shenzhen Institute of Research and Innovation, The University of Hong Kong, Shenzhen, China.

✉Corresponding author: Jianping CHEN, School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. Work Telephone Numbers +852-39176479; Fax Numbers 21684259; E-mail: abchen@hku.hk.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2022.07.07; Accepted: 2022.09.18; Published: 2022.10.03

Abstract

Fibroblast growth factor (FGF) 21 is one of the FGF members with special endocrine properties. In the last twenty years, it has attracted intense research and development for its physiological functions that respond to dietary manipulation, pharmacological benefits of improving the macronutrient metabolism, and clinical values as a biomarker of various human diseases. Generally, FGF21 can be produced by major metabolic organs, but only the subgroup from the liver shows canonical endocrine properties, which emphasizes the special value of delineating the unique secretory and functional characteristics of hepatic FGF21. There has been a growth in literature to address the extra-hepatic activities of FGF21, and many striking findings have therefore been published. Yet, they are fragmented and scattered, and controversies are raised from divergent findings. For this reason, there is a need for a systematic and critical evaluation of current research in this aspect. In this review, we focus on the current knowledge about the molecular biology of endocrine FGF21, especially present details on the regulation of circulating levels of FGF21. We also emphasize its emerging roles in inter-organ crosstalk and cancer development.

Key words: Fibroblast growth factor 21, Hepatic FGF21, Endocrine FGF21, Liver, Inter-organ crosstalk, Cancer

Introduction

The mammalian fibroblast growth factor (FGF) superfamily consists of 23 members, which are grouped into 7 subfamilies based on their sequence homology and function. FGF19 (FGF15 for mice) is the only endocrine-acting subfamily that can secrete into the circulation and function as hormones [1]. FGF21 is a member of FGF19 family identified in 2000 by Nishimura, Nakatake [2]. Over the last two decades, FGF21 has attracted great interest due to its pleiotropic metabolic effects in response to diverse physiological and pathological stress (Figure 1). With the expansion of knowledge of FGF21, our understanding of its biology is constantly undergoing modification, especially for the liver-secreted FGF21, which is considered the main source of circulating FGF21 and has been implicated in various diseases (Table 3). As a dominant metabolic organ, the liver can sense the stress from both external and internal environments, and accordingly activate its intra- and extra-organ metabolic activities [3]. The latter is realized partly via a group of proteins named hepatokines which are exclusively or predominantly secreted from the liver [4]. In this regard, there is a growing body of research that points to the role of FGF21, as a newly defined member of hepatokines, in liver-participated inter-organ communications and extra-hepatic diseases. Here, we will discuss current studies and gaps in aberrant expressions and the underlying mechanisms of hepatic FGF21 observed in inter-organ crosstalk and cancer progressions. And in light of the findings summarized in this review, we proposed that FGF21 is a sensitive hormone regulated for adaptive stress response, a potent modulator acting as an endocrine hepatokine in inter-organ crosstalk, and also a promising biomarker with pleiotropic activities in cancer progressions.
FGF21 is a sensitive hormone regulated for adaptive stress response

Mechanically, the expression and secretion of hepatic FGF21 are coordinately regulated by a set of proteins which are partly listed in Table 1. Generally, FGF21 is mainly under the control of peroxisome proliferator activated receptor α (PPARα) as an adaptive response to stress [5]. The trafficking and secretion of FGF21 are regulated by the Yip1 domain family member 6 gene, which sorts and packages FGF21 into COPII vesicles for secretion with the guidance of SEC23A [6]. As a stress-induced factor, the expression of FGF21 is closely connected with a series of biological events, such as circadian rhythm, diet intervention, exercise, and cold exposure.

Circadian rhythm

For both humans and mice, serum FGF21 shows circadian rhythm during fasting with the nocturnal rise and diurnal fall, but this pattern is largely diminished in obese individuals and under standardized meals or cold exposure [7-9]. As a circadian output gene, the FGF21 promoter contains circadian-responsive elements, and the circadian oscillation of FGF21 is therefore controlled directly by several clock proteins (Figure 2) [10-12]. Particularly, PPARα is the major activator of FGF21 via binding to PPRE sites during fasting [13], and insulin-mediated upregulation of E4BP4 suppressed FGF21 transcription via D-box under feeding [10]. In addition, while RORα activated the FGF21 promoter via an upstream RORE site, REV-ERBα negatively regulated FGF21
expression with the cooperation of HNF6 at RORE site [11, 12]. Interestingly, the circadian rhythm of FGF21 seems to be influenced by gender and fed state. Early studies reported that whether under fed or fasting states, both male and female subjects displayed circadian changes [7, 8]. But Foo, Aronis [14] later found that the day-night variation patterns of FGF21 only showed in females with standardized meals, but not in fasting state or in male subjects, which were positively correlated with circulating patterns of free fatty acid (FFA) [9, 14]. The discrepancy may be secondary to the different study designs, the race of the subjects, and the assays used. However, it indicated that sexual dimorphism exists in the circadian rhythm of FGF21.

**Table 1. The direct regulators of hepatic FGF21**

<table>
<thead>
<tr>
<th>Regulator</th>
<th>Condition</th>
<th>Correlation with FGF21 production</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peroxisome proliferator activated receptor</td>
<td>Gluconeogenesis; Adaptive starvation response</td>
<td>+</td>
<td>[5]</td>
</tr>
<tr>
<td>Farnesoid X receptor</td>
<td>Ketogenic diet</td>
<td>+</td>
<td>[125]</td>
</tr>
<tr>
<td>cAMP-responsive element-binding protein H</td>
<td>Fasting; High-fat diet</td>
<td>+</td>
<td>[126]</td>
</tr>
<tr>
<td>Nuclear receptor subfamily 4 group A member 1/Nur77</td>
<td>Fasting</td>
<td>+</td>
<td>[127]</td>
</tr>
<tr>
<td>Activating transcription factor 4</td>
<td>High-fat diet; Carbon monoxide induction; Glucagon plus insulin induction</td>
<td>+</td>
<td>[128-130]</td>
</tr>
<tr>
<td>Carbohydrate responsive-element binding protein</td>
<td>High-fructose diets</td>
<td>+</td>
<td>[131]</td>
</tr>
<tr>
<td>Aryl hydrocarbon receptor</td>
<td>2,3,7,8-tetrachlorodibenzo-p-dioxin-induced hepatotoxicity</td>
<td>+</td>
<td>[132]</td>
</tr>
<tr>
<td>Glucocorticoid receptor</td>
<td>Dexamethasone induction; Glucocorticoids induction</td>
<td>+</td>
<td>[45, 133]</td>
</tr>
<tr>
<td>Liver X receptor</td>
<td>Cholesterol-enriched diet</td>
<td>-</td>
<td>[134]</td>
</tr>
<tr>
<td>Estrogen-related receptor γ</td>
<td>Hepatic CB1 receptor-mediated induction</td>
<td>+</td>
<td>[135]</td>
</tr>
<tr>
<td>E4 binding protein 4</td>
<td>Refeeding</td>
<td>-</td>
<td>[136]</td>
</tr>
<tr>
<td>Yip1 domain family member 6 gene</td>
<td>Trafficking and secretion</td>
<td>-</td>
<td>[6]</td>
</tr>
</tbody>
</table>

**Exercise**

For both rodents and humans, exercise resulted in a significant increase in serum FGF21 levels, which were in line with the elevated lipolysis and decreased glucose levels [15, 16]. Mechanistically, the upregulated glucagon to insulin ratio during exercise contributed to the increased circulating levels of FGF21, and the concomitant blood FFA elevations may act synergistically on hepatic FGF21 secretion [15]. On the other hand, studies found that, under certain conditions, exercise could stimulate FGF21 production in the muscle, which was also associated with the increased circulating FGF21 [17]. However, divarication was observed in both human and animal-based studies [16, 18]. These paradoxical findings suggest that both muscle and liver respond to the exercise-induced elevation of circulating FGF21, but the dominance may change under different conditions. It is noted that the response of FGF21 to exercise is transient, and the sampling time is important. This may explain the lack of difference between the before and 48h after exercise [19]. Moreover, different exercise modes and sex also contributed to different outcomes. Studies found that long-term endurance exercise increased FGF21 while neither shortened time of endurance exercise nor resistance exercise changed serum FGF21 levels in men subjects [20, 21]. For women, long-term endurance training reduced baseline FGF21 levels, while resistance training significantly increased FGF21 levels [22, 23]. Even though these confusing scenarios do lend support to the idea that exercise alters circulating levels of FGF21, further study is warranted to delineate the mechanism explaining the complex patterns of FGF21 facing exercise, and both the study subject and training plan need to be carefully designed to gain more compelling evidence.

**Dietary intervention**

The sensitivity and tendency of FGF21 to dietary intervention are different between mice and humans. Both hepatic and circulating levels of FGF21 are robustly induced by fasting, high-fat diet, low-carbohydrate, and high protein ketogenic diets in mice [5, 24]. However, humans showed a more complicated response to diet intervention. Circulating FGF21 levels are not altered in humans by either shorter-term fasting or ketogenic diets, but increased by long-term fasting (7 days) or with a low-protein/high-carbohydrate diet [7, 25-27]. Besides, human FGF21 was sharply increased after 3-day overfeeding with high-fat snacks but almost returned to baseline on day 28 [28]. These findings indicated the complex intrinsic variation in FGF21 metabolism, which is regulated by both fasting and feeding signals. Moreover, a sex-dependent difference was also implicated where female mice were less sensitive than males to metabolic improvement observed following the high-carbohydrate diet corresponding with the less significant increase in circulating FGF21 level, but this difference was largely reduced after ovariectomy [27]. In view of the sexual dimorphism observed above, we can speculate that the metabolic benefits of FGF21 for diet intervention among females are regulated by ovarian steroid hormones (or the intact female reproductive system), though further study is required to reveal the underlying mechanisms.
Figure 2. The regulation of hepatic FGF21. The expression of FGF21 is tightly connected with circadian rhythm, diet intervention, exercise, and cold exposure. The circadian rhythm of FGF21 is controlled by several clock proteins. PPARα and RORα positively activate the expression of FGF21 while REV-ERBα and E4BP4 repress its transcription; Exercise stimulates FGF21 expression via the increased plasma glucagon to insulin ratio, and this process positively correlated with the elevated lipolysis and decreased glucose levels; Diet regimen has magnificent impacts on FGF21 levels, both nutrient proportions and food timing are implicated in the complex regulation system of FGF21; Increased FGF21 is also observed under cold exposure which may be cooperated with the thermogenic response of BAT to maintain body temperature.

Cold

While increased FGF21 levels, decreased half-life, and retained diurnal rhythm during cold exposure have been consistently observed in mice [29], changes in humans are still under debate. Paul Lee et al. [30] and Hanssen et al. [31] found that mild cold exposure augmented overall FGF21 levels, which were positively associated with improved body core temperature. However, some studies observed decreased plasma FGF21 levels in either short-term mild cold exposure or overweight subjects [32, 33]. It should be noted that the diurnal rhythm of plasma FGF21 was weakened but still retained under mild cold exposure [34].

On the other hand, FGF21 expanded overall thermogenic capacity by stimulating fat browning activity [30]. Therefore, brown adipose tissue (BAT) was also implicated in the regulation of FGF21 under thermogenic activation [29, 35]. Norepinephrine-stimulated increase of FGF21 outputted from interscapular BAT caused marked arteriovenous differences in FGF21 levels under cold exposure [29]. However, counterevidence has also been reported [35, 36]. In FGF21 liver-specific-KO mice, both acute cold exposure and norepinephrine-induced increases in circulating FGF21 levels were completely lost, accompanied by the markedly attenuated BAT sympathetic nerve activity and impaired BAT glucose metabolism [37, 38]. These findings support a more plausible hypothesis that cold exposure evokes the simultaneous elevation of FGF21 in the liver and BAT, wherein the BAT-divided FGF21 shows autocrine and paracrine effects on activating the thermogenic response of BAT, while hepatic FGF21 modulates the circulating FGF21 levels and signals to the central nervous system (CNS) to enhance this adaption function further.

The regulation of FGF21 is complex and still not being fully understood. In this regard, establishing strict eligibility criteria for participant selection, measuring FGF21 levels at multiple time points, and setting paired samples are indispensable for studies to decipher the precise response of FGF21 under certain conditions.

FGF21 is a potential modulator in liver-participated inter-organ crosstalk

FGF21-FGF receptors (FGFR) axis could activate a multitude of signaling cascades, including the
RAS-MAPK pathway, the JAK-STAT pathway, the PI3K-AKT pathway, the PLCγ pathway, and JNK pathways [39]. As a pleiotropic metabolic regulator, the activities of FGF21 are complex and vary in different physiological or pathophysiological context [40], and whether the liver is the direct target of FGF21 remains debatable. Hepatocytes express β-Klotho (KLB) but not FGFR1. Therefore, in vivo administration of FGF21 stimulated the response of white adipose tissue (WAT) and breast tissue but not the liver [41]. However, FGF21 enhanced hepatic fatty acid oxidation and tricarboxylic acid cycle flux [42], implicating that FGF21 exerted these hepatic actions via an indirect mechanism that may involve other secretory factors. On the other hand, as a secretory hepatokine, hepatic FGF21 is supposed to integrate liver metabolic status with systemic needs and may contribute to inter-organ communications. The aberrant expression levels of circulating FGF21 in different diseases (Table 3) show its pleiotropic effects. Up to now, the role of FGF21 has been unearthed in several organs/tissues, and the existence of FGF21-based inter-organ crosstalk was implied (Figure 3).

**Nervous system**

Though undetectable in the nervous system, FGF21 could cross the blood-brain barrier and act in the CNS [43]. Moreover, FGF receptors FGFR1c, 2, and 3c are broadly expressed in the nervous system, and co-receptor KLB is selectively expressed in the suprachiasmatic nucleus [44]. Hepatic FGF21 regulated glucocorticoid production via the CNS [45]. Also, FGF21 has defined an important liver-neuroendocrine axis to modulate the adaptive starvation response, including the regulation of circadian behavior, body weight, and insulin levels via suppressing the output of the suprachiasmatic nucleus [44]. Similarly, the caloric restriction increased hepatic expression and systemic concentration of FGF21, and FGF21 treatment showed neuroprotection effects via activating FGFR1 pathways in primary glial cells [46]. An intriguing study about gut microbiota transplantation found that the increased expressions of hepatic/systemic FGF21 and hippocampal KLB expression were positively connected with improved neurogenesis in recipients, shedding light into the link between a FGF21-based microbial and the neuron system [47].

There has been a focus on neuroprotection activities of FGF21 in brain disorders in recent years. Decreased serum FGF21 levels were detected in patients with Parkinson’s disease and Alzheimer’s disease [48, 49]. And FGF21 treatment improved...
related neural pathologies and degeneration by rescuing the astrocyte-neuron lactate shuttle system [50-52]. In this regard, the FGF21-expressing lentiviral vector and FGF21 analogue LY2405319 have been proposed as promising therapy for Alzheimer’s disease [53, 54]. However, whether these neuroprotective functions are related to the hepatic secretory FGF21 has not yet been reported. Instead, the hippocampus and cortex could secret FGF21 under neuronal mitochondrial dysfunction [55], and an increased pancreas source of FGF21 was also reported to improve CNS damage [56]. Therefore, the aberrant FGF21 levels detected in neuronal diseases (especially in conditions associated with the neuron mitochondrial and endoplasmic reticulum stress) in both brain and blood should be identified with caution, and the liver-CNS axis may help further explore the neuroprotection activities of FGF21.

**Gut microbiome**

Gut microbiota (GM) represents a mysterious group of microorganisms living in the digestive tract, and host-GM crosstalk has been discussed in various human diseases [57]. The FGF19-bile-acid-GM axis has been established and implicated in the GM-organs crosstalk, especially with the liver [58]. Hepatic FGF21 expression is influenced by GM and involved in the microbiota-gut-brain axis [47]. Moreover, decreased serum FGF21 levels were detected in *Clostridioides difficile* infection patients receiving fecal microbiota transplantation therapy [59]. Mice supplied with *B. adolescentis*, the dominant species in the human intestine, showed reduced hepatic FGF21 levels, which were believed as an improvement of the non-alcoholic fatty liver disease (NAFLD)-related FGF21 resistance state [60]. More compelling, it was found that the increased hepatic FGF21 expression of protein restriction relied on the activity of GM, and dietary fiber supplementation influenced hepatic FGF21 stress response via shifting GM composition [61]. However, the significance of GM-induced hepatic FGF21 response to bodily functions, and whether the GM-liver communication is bidirectional requires further exploration.

**Adipose tissue**

While the liver is the major contributor to circulating levels of FGF21, WAT is the target contributing greatly to the metabolic effects of FGF21. The expression of KLB in conjunction with FGFR1c in adipose tissue confers FGF21 activities there [62, 63]. The FGF21 expression level in human adipose tissue is negligible [25], which indicates that liver-secreted FGF21 is requisite for realizing the metabolic benefits of FGF21 found in adipose tissues. Along this line, studies have revealed the important role of FGF21 in liver-adipose tissue crosstalk. The elevated liver production of FGF21 in hepatic Cpt1a knockout mice contributed to the increased adipose browning and energy expenditure [64]. A recent study found that methionine adenosyltransferase *Matla* knockdown prevented and reversed obesity, insulin resistance, and hepatosteatosis via stimulating the expression and secretion of hepatic FGF21, which subsequently activated the liver-adipose tissue axis resulting in increased BAT thermogenesis, WAT lipolysis, and secretion of adiponectin [65].

The interactions between FFA and FGF21 create the loop between WAT and the liver. The FFA level in the serum of healthy individuals showed a similar oscillatory pattern with FGF21 under both fasting and feeding conditions, though the pick time was preceded. On the one hand, hepatic p38 stimulated WAT lipolysis and FFA release via upregulating FGF21 secretion from the liver to WAT [66]. On the other hand, a low dosage of FFA treatment stimulated FGF21 secretion in HepG2 cells [8]. And growth hormone-stimulated release of FFA from WAT resulted in the CREBH/PPARα-mediated over-expression of hepatic FGF21, which in turn suppressed WAT lipolysis [67, 68]. Notably, a study found that only unsaturated FFA could induce hepatic FGF21 expression [8]. Considering the FFA composition is different in different sites of WAT [69], it is worth uncovering whether their effects on hepatic FGF21 are also site specific.

Adiponectin is the most abundant adipokine secreted by adipocytes [70]. Intriguingly, recent studies have started to delineate the positive interactions between FGF21 and adiponectin. A study found that hepatic FGF21 induced the biosynthesis and secretion of adiponectin in adipocytes, which in turn conferred FGF21 systematic and hepatic functions through positive feedback [71]. And WAT adiponectin was reduced in FGF21-KO mice but was completely restored after FGF21 replenishment [72]. Furthermore, both acute and chronic administration of FGF21 increased circulating adiponectin levels, and adiponectin deficiency diminished the metabolic effects of FGF21 on glucose tolerance and insulin resistance [71]. Magnificently, the study found that JNK deficiency-induced adipocyte FGF21 upregulation triggered a feed-forward loop in the liver-WAT axis, which promoted hepatocyte FGF21 expression and secretion via regulating adipocyte adiponectin expression and secretion [73]. These findings represent an unfolding story about the interactions between FGF21 and adipokine.
Heart

The evaluated levels of FGF21 were predictive of poor outcomes in cardiac diseases [74, 75] (Table 3). Interestingly, one recent study detected that the cardiac FGF21 gene expression levels in heart failure patients were as low as healthy subjects, but the protein levels of FGF21 in both the serum and cardiac section were aberrantly increased and accompanied by elevated cardiac FGFR3 expression, which indicated the existence of a FGF21-dependent cardiohepatic signaling circuit [74]. Consistently, hepatic FGF21 maintained chronicity in mice during bacterial inflammation [76]. Mice cardiomyocytes express FGFRs and KLB, and the activated PI3K-Akt and ERK signaling pathways partly contributed to the cardiac benefits of FGF21 [77, 78]. However, the mechanism of FGF21 cardioprotective actions is still under debate, and the existence of the FGF21-based liver-brain axis remains to be proved. For example, cardiomyocytes were not only a target but also a source of FGF21 [78]. KLB expression was disease in cardiac dysfunction, and in vivo FGF21 treatment failed to activate ERK signaling in the heart [76]. These findings indicated that both systemic and cardiac FGF21 had cardioprotective activities via direct, indirect, or both pathways.

Retina/Choroid

Retinal and choroidal ocular pathologic neovascularization is aggravated in FGF21 knockout mice and suppressed via the FGF21 analog-activated adiponectin pathway [79]. FGF21 depletion also resulted in the increased occurrence of dry macular degeneration-like pathological changes, while exogenous FGF21 administration reversed this phenomenon [80]. A later study found that FGF21 prevented VEGF-induced retinal vascular leakage in mice and strengthened human primary retinal microvascular endothelial cells barrier function [81]. However, it is still unclear whether circulating or local FGF21 contributed to these protective effects. Considering the extremely low/absent expression of FGF21 detected in the visual system [82], it is plausible to postulate that the protective effect of FGF21 on the eye is mainly realized by the circulating FGF21, though further studies are necessary.

The data discussed above indicate that the aberrant expressions of FGF21 observed in circulation and organs in different contexts are likely to be an ex officio action of the liver to realize the pleiotropic effects of FGF21, especially regarding the adaptive starvation response in the CNS system, nutrition metabolism in GM, and energy homeostasis in adipose tissue. A crosstalk network is therefore delineated between the liver and other organs/tissues, which is no doubt striking and should be an area of fruitful future study.

FGF21 is a promising biomarker with pleiotropic activities in cancer progressions

As a stress-responsive hepatokine, the implications of FGF21 in cancers have been focused on in recent years. Overall, overexpression of FGF21 in both circulating and tissue levels has been found in different types and clinical stages of cancers (Figure 4, Table 2), suggesting the biomarker value of FGF21 in cancer diagnosis and treatment. Theoretically, the well-studied findings of the oncogenic FGF-FGFR axis attest to this hypothesis. FGF21-related FGF receptors FGFR1c, 2c, 3c, and 4 are widely expressed in tumor cells and aberrantly activated in cancers [83]. The deregulation of FGF expression drives oncogenic FGF signaling and activates downstream signaling through MARK-ERK, PI3K-AKT, and JAK-STAT pathways that regulate tumor cell proliferation, differentiation, and survival [84]. Another plausible reason for FGF21 participating in cancers is its high sensitivity to macronutrients. Imbalanced nutrition intake is not only a cause of carcinogenesis but also occurs during cancer progression. In this setting, recruiting FGF21 from either adjacent or distant organs will benefit tumor tissues against adverse environments. This may partially explain the elevated circulating and peritumoral FGF21 levels observed in cancer patients [85, 86]. However, in a low-protein ketogenic diet, FGF21 knockout mice showed a comparable decrease in tumor growth to that of the wild type [87]. Therefore, although the aberrant expression of FGF21 was a sensitive response to diet intervention, whether it benefits anti-cancer activities in low protein diets and ketogenic diets or plays a part in countering obese diets requires further study [88].

Liver cancer

The close relationship between the liver and FGF21 aroused researchers’ attention to the role of FGF21 in liver cancers. Accumulated data gave us a relatively deeper understanding of the FGF21-liver cancer axis compared to other cancers. Though FGFR4 is the major FGFR present in mature hepatocytes, elevated expression of FGFR1 has been observed in hepatocellular carcinoma (HCC) and contributed to tumor development [89]. This aberrant expression appears to be more favorable for FGF21’s binding. Consistently, both liver and serum levels of FGF21 were upregulated in patients with hepatitis, cirrhosis, and liver tumors, and associated with a significantly decreased survival rate in patients with inferior
hepatocellular carcinoma [90]. For the carcinogen-induced HCC animal model, increased FGF21 levels were observed in the early and middle stages of tumorigenesis, and also in normal hepatocytes adjacent to the tumor foci, while sharply diminished once cells progressed to malignancy. This change indicated that FGF21 is an independent indicator of genetic hepatocarcinogenesis, but its expression is not a direct genetic marker of hepatoma cells per se [91]. Instead, a study showed that canopy homolog 2 promoted liver oncogenesis via destabilizing p53 and activating hepatic FGF21 expression [92]. Consistently, tumor suppressor miR-22 reduced hepatic FGFR1 by direct targeting and inhibited FGF21 expression by reducing its synthesis process [93]. Moreover, FGF21 knockout mice were more sensitive to a high fat, high sucrose diet-induced HCC [95], which was later proven through FGF21’s negative feedback on hepatocyte-TLR4-IL-17A signaling [96]. And FGF21 knockout accelerated autophagy gene Atg7 deletion induced hepatic tumor process, implicating the suppressive effect of FGF21 on autophagy-insufficient hepatoma [97]. Besides, the overexpression of FGF21 delayed the tumor incidence in the diethylnitrosamine-induced liver cancer mice model, but contrarily accelerated the progression of adenoma to HCC, resulting in similar HCC outcomes between overexpression and wild-type groups [98]. Also, the distinct effects of long-term pharmacological dosage of FGF21 on HCC were observed between rats and mice [99], indicating that the pharmacological effects of FGF21 on hepatoma may be highly susceptible to species and treatment regimens.

### Table 2. The correlations and activities of FGF21 in cancers

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Clinical study</th>
<th>In vivo study</th>
<th>In vitro study</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Serum FGF21 levels were different in different stages of tumorigenesis; Intratumoral FGF21 knockdown inhibited sorafenib-resistant HCC; Deficiency of FGF21 promoted obesogenic diet-induced HCC; FGF21 knock out promoted autophagy-deficient hepatoma; Overexpression of FGF21 or exogenous FGF21 treatment delayed carcinogen-induced HCC tumorigenesis; FGF21 treatment promotes carcinogen-induced HCC tumorigenesis in rats.</td>
<td>Overexpression of FGF21 increased sorafenib resistance; FGF21 treatment suppressed carcinogen-induced oxidative stress.</td>
<td>[89-91, 94, 95, 97, 99]</td>
<td></td>
</tr>
<tr>
<td>Liver cancer</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer</td>
<td>+</td>
<td>Undetectable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Unknown</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td>Unknown</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>Unknown</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Unknown</td>
<td>-</td>
<td>Pharmacological supplementation of FGF21 delayed cancer development under obesogenic diet challenge.</td>
<td>[104]</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>+</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal cancer</td>
<td>+</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>+</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>+</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid carcinoma</td>
<td>+</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urothelial carcinoma</td>
<td>+</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 4. Hepatic FGF21 is a promising biomarker for cancers. Aberrant expression of FGF21 has been correlated with cancer development. Accumulating data indicated the predictive and diagnostic values of FGF21 as a promising biomarker for human cancers, for some of which its underlying mechanisms have been discussed.

Table 3. FGF21 is a promising biomarker for risk prediction and diseases progression

<table>
<thead>
<tr>
<th>Disease</th>
<th>Correlation with circulating FGF21</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAFLD</td>
<td>+</td>
<td>[137, 138]</td>
</tr>
<tr>
<td>Hepatic ischemia/reperfusion injury in patients with liver transplantation</td>
<td>-</td>
<td>[139]</td>
</tr>
<tr>
<td>Genotype-4 chronic hepatitis C</td>
<td>+</td>
<td>[140]</td>
</tr>
<tr>
<td>Advanced fibrosis/cirrhosis in chronic hepatitis B patients on antiviral treatment</td>
<td>-</td>
<td>[141]</td>
</tr>
<tr>
<td>Carotid atherosclerotic diseases</td>
<td>+</td>
<td>[142]</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>+</td>
<td>[75, 143]</td>
</tr>
<tr>
<td>Heart failure</td>
<td>+</td>
<td>[74]</td>
</tr>
<tr>
<td>Vascular calcification</td>
<td>+</td>
<td>[144]</td>
</tr>
<tr>
<td>Adverse cardiovascular events in patients with type 2 diabetes</td>
<td>+</td>
<td>[145]</td>
</tr>
<tr>
<td>Adverse cardiovascular events in ST-segment elevation myocardial infarction patients</td>
<td>+</td>
<td>[146]</td>
</tr>
<tr>
<td>Adverse clinical events in patients with myocardial infarction who have undergone coronary artery bypass graft</td>
<td>+</td>
<td>[147]</td>
</tr>
<tr>
<td>Diabetes</td>
<td>+</td>
<td>[148]</td>
</tr>
<tr>
<td>Obesity</td>
<td>+</td>
<td>[149]</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>+</td>
<td>[150]</td>
</tr>
<tr>
<td>Renal disease</td>
<td>+</td>
<td>[151]</td>
</tr>
<tr>
<td>Mitochondrial disease/mitochondrial myopathies</td>
<td>+</td>
<td>[152]</td>
</tr>
<tr>
<td>Pediatric mitochondrial disease</td>
<td>+</td>
<td>[153]</td>
</tr>
<tr>
<td>Primary sarcopenia</td>
<td>+</td>
<td>[154]</td>
</tr>
<tr>
<td>Dravet syndrome</td>
<td>+</td>
<td>[155]</td>
</tr>
<tr>
<td>Pterygium</td>
<td>-</td>
<td>[156]</td>
</tr>
<tr>
<td>Missed abortion</td>
<td>+</td>
<td>[157]</td>
</tr>
<tr>
<td>Mortality of patient with sepsis and acute respiratory distress syndrome</td>
<td>+</td>
<td>[158]</td>
</tr>
</tbody>
</table>

Thyroid cancer

Serum FGF21 levels were significantly higher in the papillary thyroid carcinoma patients than in controls and were positively associated with pathological stage, recurrence, and mortality. In vitro FGF21 treatment promoted tumor cell migration and invasion by upregulating FGFR-EMT signaling. It is worth noting that FGF21 expression was detected in neither normal thyroid tissues nor tumor tissues, which indicated that FGF21 might induce thyroid tumor progression in an endocrine way [85].

Prostate cancer

FGF21 expression was decreased in clinic prostate cancer tissues, and overexpression of FGF21 inhibited prostate cancer cell viability [100]. But whether the decreased FGF21 levels in tumor tissues were due to the decreased circulating FGF21 needs to be confirmed. Besides, using high glucose conditions to strengthen cell viability seems uncalled for considering cancer cells’ commonality of uncontrolled proliferation and anti-apoptosis abilities. Furthermore, it may lead to the effects of FGF21 on cancer cells easily overshadowed by its outstanding regulation ability of glucose metabolism, which the author also mentioned.
**Non-small cell lung cancer**

FGF21 was upregulated in non-small cell lung cancer tissues, and the higher expression level was associated with shorter overall survival time and advanced histological type. *In vitro* study showed that FGF21 was elevated in tumor cells compared with normal lung cell lines, which facilitated tumor progression by promoting cell growth, migration, and defending oxidative stress via Siruut1/P13K/AKT signaling [86]. Moreover, FGF21 expression was suppressed in TWIST2-overexpressed lung cancer cells, resulting in decreased cell viability, increased oxidative stress, and cell apoptosis [101]. However, current research only focused on the autocrine function of FGF21 in lung cancers. Thus future studies concentrating on the interplay between the endocrine form of FGF21 and lung tumor tissues are encouraged.

**Melanoma**

Overexpression of FGF21 in mouse melanoma cell line enhanced cell aggressiveness and tumorigenicity under hypoxia and low-nutrition double deprivation stress [102]. However, FGF21 serum levels were negatively connected with the metastatic ability of melanoma cells in animals, and exogenous FGF21 treated macrophage inhibited melanoma cell viability via intercellular crosstalk in a dose-dependent manner [103]. This controversy reflected the pleiotropic actions of FGF21 in melanoma and the tumor microenvironment.

**Pancreatic cancer**

The circulating levels of FGF21 in pancreatic cancer patients are still unclear, but both pancreatic cancer specimens and cell lines had lower levels of FGF21 than normal human pancreatic tissues and cells, respectively. The pharmacological dosage of FGF21 supplementation effectively inhibited pancreatic intraepithelial neoplasia lesions, inhibited liver metastasis, and prolonged the overall survival of KRAS-mediated pancreatic cancer under the high-fat-diet challenge. Though serum FGF21 level was not influenced by pancreatic KRAS mutation, the effect of pathological levels of circulating FGF21 under a high-fat diet, in turn, on pancreatic tumor development was not addressed [104]. Moreover, KRAS, the most frequently mutated RAS isofrom, happens not only in pancreatic cancer but also in lung cancer, multiple myeloma, and colorectal cancer [105]. Whether this KRAS-FGF21 axis exists in other types of cancer and the distinctions between different mutant hotspots deserve further study.

**Breast cancer, Renal cancer and Colorectal cancer**

As mentioned, adipose tissue is not only a source of autocrine FGF21 but also a direct and predominant target of hepatic FGF21, which may result in a substantial enrichment of FGF21 in the microenvironment of the tumors growing in the anatomical vicinity of adipose tissue, such as breast, renal and colon cancers. Even though the activities of FGF21 in these types of cancers have not been explored yet, elevated serum levels of FGF21 were reported in the early stages of breast cancer [106] but significantly reduced following 12 months of hormonal therapy [107]. Patients with both clear renal cell carcinoma and chromophobe renal cancer had higher levels of serum FGF21 compared with healthy control [108]. Also, FGF21 has shown positive associations with colon site cancer, stage I-II colorectal cancer, advanced colorectal neoplasia, and even in cases collected over 5 years before diagnosis, which indicated that FGF21 is potentially predictive and possibly existing in colorectal cancer etiology [109-111]. Compatible with these findings, higher circulating levels of FGF21 increased the risk of metachronous colorectal adenomas, especially in the older population [112]. These limited data suggest the great suitability of serum FGF21 as a diagnostic biomarker of cancers, and also open the door for the speculation that an FGF21-driven liver-adipose tissue-tumor tissue axis is implicated in cancers.

**Other cancers**

Increased FGF21 levels were observed in patients with different stages of gastric cancer, suggesting it is a suitable biomarker for early-stage gastric cancer [113]. Also, serum FGF21 level was higher in patients with endometrioid carcinoma, sufficing it to diagnose the cancer stage and grade [114]. Similarly, in urothelial carcinoma, serum FGF21 level was positively associated with the tumor stage, cardiovascular disease, and history of recurrence [115].

So far, there is limited information available to explain the role of FGF21 in tumor initiation and progression. Though the results listed above are promising, they need more detailed and in-depth investigations as it is hard to discern whether the increased level of FGF21 contributes to cancer development or is just a result of carcinogenesis or a stress response for maintaining body system homeostasis. As a potential biomarker, the aberrant expression of FGF21 has been generally observed in different types and stages of cancers, which indicates its low specificity. Instead, FGF21 may be an ideal non-invasive biomarker applied in regular health tests.
for discovering and preventing cancers at an early stage, though the sensitivity and cancer-specificity for clinical use need to be evaluated critically.

Discussion

Since 2000, the scientific appreciation of FGF21 in various human diseases has been rapidly expanding. As an unfolded area, the increasing roles of FGF21 generate a series of inspiring ideas, such as whether exclusive FGF21 secretion ability confers liver extra-hepatic functions, whether endocrine FGF21 is the holistic hub point for interorgan crosstalk, whether there are concomitant modulators that collaborate with FGF21 or whether FGF21 is an actionable biomarker with therapeutic values for cancers. However, studies in this area are still in their infancy. To boost the research process of FGF21, several factors need to be considered.

The first factor is about distinguishing between pathological and pharmacological doses of FGF21. The physiological actions of FGF21 occur at much lower concentrations and in more restricted organ systems and tissues than its pharmacological actions [40]. Both long-term administrations of pharmacological dosage of FGF21 and transgenic mice over-expressing FGF21 did not develop liver tumor or show evidence of any other tissue hyperplasia, which potently denied the carcinogenic risk of FGF21 therapy [116, 117]. Future studies regarding the role of aberrant pathological levels of FGF21 in cancer progression are therefore recommended. The distinction between pathological and pharmacological levels of FGF21 did not receive adequate attention in previous studies. The highly inconsistent dosage selection was observed in studies that were all focused on the pharmacological actions of FGF21 [99, 104]. Furthermore, converting in vitro concentrations to in vivo doses (and vice versa) is even thornier since it is hard to set a clear line between pathological and pharmacological dosages for in vitro study. In this case, in vivo study is more reliable for observing the biological effects of FGF21 under different conditions.

Secondly, the elimination half-life of FGF21 is only 0.5~2 hours [116, 118]. Thus selecting the appropriate administration dosage and mode is important and highly dependent on the objective of your research. Even though a study indicated that FGF21 action did not require the prolonged presence of the actual protein in circulation, approximately a 10-fold greater dose of FGF21 was needed for a once-daily subcutaneous injection to achieve an equivalent body weight reduction compared with continuous FGF21 administration via osmotic pump [116]. Since continuous infusion allows the stable presence of circulating FGF21 levels throughout the course of the study, it is particularly suitable for studying the long-term effects of FGF21 (such as mimicking the overall increased FGF21 levels in metabolic diseases or testing the chronic therapeutic efficacy of FGF21). Furthermore, the bioactivity of recombinant FGF21 protein should also be evaluated with caution. It should be realized that different purification and activity, combined with the non-standardized selection of dosage and administration mode, will leave non-negligible impacts on the results and further contribute to the inconsistencies between studies.

Besides, the similarities and differences between mice and humans need to be considered. While it may sound hypercritical, the aforementioned distribution and activity difference between human and mouse FGF21 warn us of the existence of species specificity in various contexts. Therefore, the clinical translation of FGF21 activities demonstrated in mice to humans needs to be further investigated. For example, mouse adipose tissues express detectable levels of FGF21, which has been implicated in the magnificent effects of FGF21 on energy metabolism. However, human adipose tissues do not express FGF21, which questions the clinical value of autocrine activities of adipose FGF21 observed in rodent-based studies [119]. Also, studies found that a significant percentage of circulating human FGF21 is not active due to fibroblast activation protein-mediated post-translation and inactivation. In contrast, mouse FGF21 is resistant to cleavage because of the different C-terminus [118, 120]. The conjunction of these overlooked differences may finally contribute to the lower-than-expected translation efficacy of FGF21-based therapeutic benefits from bench to bedside [121].

Last but not least, it is plausible that the physiology and function of FGF21 may be sexual dimorphism considering the substantial difference between genders in sex hormone levels and macronutrient metabolism patterns. Besides the different sensitivity to circadian rhythms [9, 14], exercise [20, 21], and diet [27], pharmacological levels of FGF21 showed stronger metabolic effects in males and were antagonized by estradiol replenishment in ovariectomized females [122, 123]. However, endogenous hepatic FGF21 transcription is positively regulated by the estradiol-Wnt pathway in a PPARα-independent way, which resulted in reduced hepatic FGF21 production in female mice following ovariectomy [124]. These findings suggest a notable role of estrogen in FGF21 activities. Sexual dimorphism is a new frontier in FGF21 research, so future studies concentrating on this difference, especially unearthing the orchestrated interactions...
between FGF21 and estrogen, will expand our understanding of FGF21 biology.

**Conclusion**

Focusing on FGF21, the findings discussed in this review indicated its high sensitivity to adaptive stress response, its important role in modulating liver-participated inter-organ crosstalk, and its potential value in cancer diagnosis and treatment. In-depth studies to establish a comprehensive framework of the biology and activities of endocrine FGF21 are called upon.

**Abbreviations**

FGF: fibroblast growth factor; PPARα: peroxisome proliferator activated receptor α; BAT: brown adipose tissue; CNS: central nervous system; WAT: white adipose tissue; GM: gut microbiota; COPII: coat Protein Complex II; RORα: retinoic acid-related orphan receptor alpha; HNF6: hepatocyte nuclear factor 6; FFA: free fatty acid; FGF21: fibroblast growth factor receptor; MAPK: mitogen-activated protein kinase; JAK: Janus kinase; STAT: signal transducer and activator of transcription protein; PI3K: phosphoinositide 3 kinase; AKT: serine/threonine-protein kinase; PLCγ: phospholipase C gamma; JNK: c-Jun N-terminal kinase; KLB: β-klotho; NAFLD: non-alcoholic fatty liver disease; VEGF: vascular endothelial growth factor; ERK: extracellular signal-regulated kinases; HCC: hepatocellular carcinoma; TLR4: toll-like receptor 4; IL-17A: interleukin 17A; Atg7: autophagy related 7; EMT: epithelial–mesenchymal transition; TWIST2: twist family BHLH transcription factor 2; KRAS: Kirsten rat sarcoma virus; RAS: rat sarcoma virus.

**Supplementary Material**

Supplementary information.

https://www.jibs.com/v18p5928s1.pdf

**Acknowledgements**

All figures were created with BioRender.com.

**Funding**

This study was supported by the National Science Foundation of China (81573663) and Guangxi Science and Technology Key Research and Development Program (AB16450008).

**Ethics approval and consent to participate**

This research was based on the review of published/publicly reported literature and did not require ethical approval.

**Author contributions**

Yue SUI wrote the article. Jianping CHEN designed and reviewed the manuscript. All authors read and approved the final paper.

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

22. Pérez-López A, Gonzalo-Encabo P, Pérez-Köhler B, García-Honduvilla N, Valadés D. Circulating myokines IL-6, IL-15 and FGF21 response to training is


Author Biography

Dr. Jianping CHEN is with the School of Chinese Medicine, the University of Hong Kong. She has coauthored over 80 publications and holds four patents. The current research interests in Dr. CHEN’s group include: (1) Prevention and treatment of breast cancer with Traditional Chinese Medicine; (2) The implication of liver dysfunction and metabolic disorder in breast cancer development.

Yue SUI is currently a Ph.D. student at the University of Hong Kong. Her research is centered on the pathogenesis and treatment of breast cancer.